Syneos Health, a research company specialising in supporting companies with late-stage clinical trials, has signed a multi-year agreement with tech company Microsoft, to use its artificial intelligence (AI) technologies.
Utilising Microsoft Azure services, Syneos Health has developed an advanced analytics platform, using machine learning to support the analysis, design, and execution of clinical trials and commercial programs.
The agreement includes collaboration with Microsoft Research and leverages developments from OpenAI. Through this collaboration, Syneos Health will deliver technology and data solutions with Microsoft that accelerate clinical development and elevate commercial performance for biopharma customers.
“Microsoft is the ideal technology partner for Syneos Health,” said Michelle Keefe, CEO, Syneos Health. “Their clear industry leadership in AI and their pragmatic approach to improving healthcare outcomes for patients, science and industry is completely aligned with our value proposition”.
Click here to read the original news story.